Champions Oncology Reports Record Annual Revenue of $57 Million
Rhea-AI Summary
Champions Oncology (NASDAQ:CSBR) reported strong financial results for fiscal year 2025, achieving record annual revenue of $57 million, representing a 14% year-over-year increase. The company demonstrated significant profitability improvements with net income of $4.6 million and adjusted EBITDA income of $7.1 million, compared to an adjusted EBITDA loss in the previous year.
Key highlights include the successful launch of a high-margin data business generating $4.7 million in data license revenue, improved gross margins reaching 50% (up from 41%), and a strong cash position of $9.8 million with no debt. However, Q4 showed some challenges with revenue declining 12% to $12.3 million and an adjusted EBITDA loss of $1.2 million.
Positive
- Record annual revenue of $57 million, up 14% year-over-year
- Achieved profitability with net income of $4.6 million, compared to previous losses
- Strong adjusted EBITDA of $7.1 million, versus -$3.9 million last year
- New data licensing business generated $4.7 million in high-margin revenue
- Improved gross margin to 50% from 41% in previous year
- Healthy balance sheet with $9.8 million cash and no debt
- Operating costs decreased 9% to $52.4 million through efficiency improvements
Negative
- Q4 revenue declined 12% year-over-year to $12.3 million
- Q4 adjusted EBITDA loss of $1.2 million, down from $884,000 income last year
- Q4 gross margin contracted to 41% from 48% in prior year
- Sales and marketing expenses increased 30% in Q4
News Market Reaction 4 Alerts
On the day this news was published, CSBR declined 14.19%, reflecting a significant negative market reaction. Argus tracked a trough of -12.7% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $18M from the company's valuation, bringing the market cap to $107M at that time. Trading volume was very high at 4.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Total annual revenue growth of
HACKENSACK, NJ / ACCESS Newswire / July 23, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2025.
Fourth Quarter Financial Highlights:
Total revenue of
$12.3 million Adjusted EBITDA loss of
$1.2 million New data licensing revenue of approximately
$200,000 Operating cash flow of
$6.4 million
Fiscal Year 2025 Financial Highlights:
Record annual revenue of
$57 million , an increase of14% year-over-yearNet income of
$4.6 million Adjusted EBITDA income of
$7.1 million Data license revenue of
$4.7 million Year-end cash balance of
$9.8 million
Ronnie Morris, CEO of Champions, commented, "This past year was pivotal for the Company, as we returned to growth and profitability, launched a high-margin data business and laid the foundation for long-term value creation". Added Morris, "With a strong pipeline heading into fiscal 2026, we're confident in our ability to drive continued revenue growth and further accelerate the monetization of our data offering."
David Miller, CFO of Champions added, "Our financial turnaround in fiscal 2025 was driven by disciplined execution and operational efficiency. We delivered record adjusted EBITDA, and strengthened our balance sheet, all while investing in scalable growth. We believe we're well positioned to build on this momentum in fiscal 2026."
Fourth Quarter Financial Results
Total oncology revenue for the fourth quarter of fiscal 2025 was
For the fourth quarter of fiscal 2025, Champions reported a loss from operations of
Cost of oncology revenue was
Research and development expense was
Net cash provided by operating activities for the quarter was approximately
Year-to-Date Financial Results
Total oncology revenue for fiscal year 2025 was
For the twelve months ended April 30, 2025, Champions reported income from operations of
Cost of oncology revenue was
Research and development expense was
Net cash provided by operations was
Conference Call Information:
The Company will host a conference call today at 4:30 p.m. EST (1:30 p.m. PST) to discuss its fourth quarter financial results. To participate in the call, please call 888-506-0062 (domestic) or 973-528-0011 (international) ten minutes ahead of the call and enter the access code 792442. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 52754, or by accessing the investors section of the company's website within 72 hours.
Full details of the Company's financial results will be available on, or before, July 23, 2025 and no later than Tuesday July 29, 2025 in the Company's Form 10-K at https://www.championsoncology.com.
* Non-GAAP Financial Information
This press release contains "Non-GAAP financial measures," which are measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with U.S. generally accepted accounting principles ("GAAP").
A further explanation and reconciliation of these Non-GAAP financial measures is included below and in the financial tables in this release.
The Company believes that the Non-GAAP financial measures presented facilitate an understanding of operating performance and provide a meaningful comparison of its results between periods. The Company's management uses Non-GAAP financial measures to, among other things, evaluate its ongoing operations in relation to historical results and for internal planning and forecasting purposes. Adjusted EBITDA and Adjusted EPS represent measures that we believe are customarily used by investors and analysts to evaluate the financial performance of companies in addition to the GAAP measures that we present. Our management also believes that these measures are useful in evaluating our core operating results. However, Adjusted EBITDA and Adjusted EPS are not measures of financial performance under accounting principles generally accepted in the United States of America and should not be considered an alternative to net income, operating income, or EPS as indicators of our operating performance or to net cash provided by operating activities as a measure of our liquidity. We believe the Company's Adjusted EBITDA and Adjusted EPS measures provide information that is directly comparable to that provided by other peer companies in our industry, but other companies may calculate Non-GAAP financial results differently, particularly related to nonrecurring, unusual items.
Adjusted EBITDA
Adjusted EBITDA represents net income (loss), or net income (loss) from operations, excluding the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.
Adjusted Net Income (Loss) and Adjusted Earnings Per Share (EPS)
Adjusted net income (loss) (if denoted) and adjusted EPS exclude the effect of stock-based compensation and depreciation and amortization and may also exclude other items not indicative of our ongoing operating performance, when defined.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
This press release may contain "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2025 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.
Media Contact
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
518 488 9026
Champions Oncology, Inc.
(Dollars in thousands)
Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (Non-GAAP) (Unaudited)
Three Months Ended April 30, | Twelve Months Ended April 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Net income (loss) - GAAP | $ | (1,834 | ) | $ | (109 | ) | $ | 4,701 | $ | (7,276 | ) | |||||
Less: | ||||||||||||||||
Stock-based compensation | $ | 131 | $ | 263 | $ | 654 | $ | 1,118 | ||||||||
Depreciation and amortization | $ | 394 | $ | 457 | $ | 1,640 | $ | 1,867 | ||||||||
Loss on equipment disposal | $ | 293 | $ | 354 | $ | 293 | $ | 435 | ||||||||
Adjusted EBITDA - Non-GAAP | $ | (1,016 | ) | $ | 965 | $ | 7,288 | $ | (3,856 | ) | ||||||
Reconciliation of GAAP EPS to Non-GAAP EPS (Unaudited)
Three Months Ended April 30, | Twelve Months Ended April 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
EPS - GAAP, basic | $ | (0.13 | ) | $ | (0.01 | ) | $ | 0.34 | $ | (0.54 | ) | |||||
Less: | ||||||||||||||||
Effect of stock-based compensation on EPS | $ | 0.01 | $ | 0.02 | $ | 0.05 | $ | 0.08 | ||||||||
Effect of depreciation and amortization on EPS | $ | 0.03 | $ | 0.03 | $ | 0.12 | $ | 0.14 | ||||||||
Effect of loss on equipment disposal on EPS | $ | 0.02 | $ | 0.03 | $ | 0.02 | $ | 0.03 | ||||||||
Adjusted EPS - basic, Non-GAAP | $ | (0.07 | ) | $ | 0.07 | $ | 0.53 | $ | (0.29 | ) | ||||||
Three Months Ended April 30, | Twelve Months Ended April 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
EPS - GAAP, diluted | $ | (0.13 | ) | $ | (0.01 | ) | $ | 0.33 | $ | (0.54 | ) | |||||
Less: | ||||||||||||||||
Effect of stock-based compensation on EPS | $ | 0.01 | $ | 0.02 | $ | 0.05 | $ | 0.08 | ||||||||
Effect of depreciation and amortization on EPS | $ | 0.03 | $ | 0.03 | $ | 0.11 | $ | 0.14 | ||||||||
Effect of loss on equipment disposal on EPS | $ | 0.02 | $ | 0.03 | $ | 0.02 | $ | 0.03 | ||||||||
Adjusted EPS - diluted, Non-GAAP | $ | (0.07 | ) | $ | 0.07 | $ | 0.51 | $ | (0.29 | ) | ||||||
Condensed Consolidated Statements of Operations (Unaudited)
Three Months Ended April 30, | Twelve Months Ended April 30, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Oncology revenue | $ | 12,355 | $ | 14,001 | $ | 56,944 | $ | 50,155 | ||||||||
Costs and operating expenses: | ||||||||||||||||
Cost of oncology revenue | 7,271 | 7,250 | 28,389 | 29,401 | ||||||||||||
Research and development | 1,963 | 2,049 | 6,825 | 9,544 | ||||||||||||
Sales and marketing | 2,309 | 1,776 | 7,545 | 7,064 | ||||||||||||
General and administrative | 2,525 | 2,762 | 9,339 | 11,067 | ||||||||||||
Loss on disposal of equipment | 293 | 354 | 293 | 435 | ||||||||||||
Income (loss) from operations | $ | (2,006 | ) | $ | (190 | ) | $ | 4,553 | $ | (7,356 | ) | |||||
Other income (expense), net | 42 | (1 | ) | 73 | 48 | |||||||||||
Net income (loss) before benefit for income taxes | $ | (1,964 | ) | $ | (191 | ) | $ | 4,626 | $ | (7,308 | ) | |||||
Benefit for income taxes | (130 | ) | (82 | ) | (75 | ) | (32 | ) | ||||||||
Net income (loss) | $ | (1,834 | ) | $ | (109 | ) | $ | 4,701 | $ | (7,276 | ) | |||||
Net income (loss) per common share outstanding | ||||||||||||||||
basic | $ | (0.13 | ) | $ | (0.01 | ) | $ | 0.34 | $ | (0.54 | ) | |||||
diluted | $ | (0.13 | ) | $ | (0.01 | ) | $ | 0.33 | $ | (0.54 | ) | |||||
Weighted average common shares outstanding | ||||||||||||||||
basic and diluted | 13,753,575 | 13,593,758 | 13,659,786 | 13,547,604 | ||||||||||||
and diluted | 13,753,575 | 13,593,758 | 14,266,781 | 13,547,604 | ||||||||||||
Condensed Consolidated Balance Sheets as of
April 30, 2025 | April 30, 2024 | |||||||
Cash | $ | 9,785 | $ | 2,618 | ||||
Accounts receivable | 11,234 | 9,526 | ||||||
Prepaid expenses and other current assets | 1,350 | 1,495 | ||||||
Total current assets | 22,369 | 13,639 | ||||||
Property and equipment, net | $ | 4,375 | $ | 5,721 | ||||
Operating lease right-of-use assets, net | 5,080 | 6,252 | ||||||
Other long term assets | 185 | 15 | ||||||
Goodwill | 335 | 335 | ||||||
Total assets | $ | 32,344 | $ | 25,962 | ||||
Accounts payable | 4,248 | 5,800 | ||||||
Accrued liabilities | 2,556 | 2,160 | ||||||
Current portion of operating lease liabilities | 1,471 | 1,337 | ||||||
Other current liability | 135 | 150 | ||||||
Deferred revenue | 15,443 | 12,094 | ||||||
Total current liabilities | 23,853 | 21,541 | ||||||
Non-current portion operating lease liabilities | 4,634 | 6,093 | ||||||
Other non-current liabilities | 85 | 401 | ||||||
Stockholders' equity (deficit) | 3,772 | (1,903 | ) | |||||
Total liabilities and stockholders' equity (deficit) | $ | 32,344 | $ | 26,132 | ||||
Condensed Consolidated Statements of Cash Flows (Unaudited)
Twelve Months Ended | ||||||||
2025 | 2024 | |||||||
Cash flows from operating activities: | ||||||||
Net income (loss) | $ | 4,701 | $ | (7,276 | ) | |||
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||||||||
Stock-based compensation expense | 654 | 1,118 | ||||||
Depreciation and amortization expense | 1,640 | 1,867 | ||||||
Operating lease right of use assets | 1,172 | 1,066 | ||||||
Net loss on disposal of equipment | 293 | 435 | ||||||
Allowance and estimated credit losses | (272 | ) | 476 | |||||
Decrease in uncertain tax position | (181 | ) | - | |||||
Changes in operating assets and liabilities | (621 | ) | (3,823 | ) | ||||
Net cash (used in) provided by operating activities | 7,386 | (6,137 | ) | |||||
Cash flows from investing activities: | ||||||||
Purchases of property and equipment | (389 | ) | (836 | ) | ||||
Net cash used in investing activities | (389 | ) | (836 | ) | ||||
Cash flows from financing activities: | ||||||||
Finance lease payments | (150 | ) | (146 | ) | ||||
Repurchases of common stock | - | (634 | ) | |||||
Proceeds from exercise of options | 320 | 253 | ||||||
Net cash provided by (used in) financing activities | 170 | (527 | ) | |||||
Increase (decrease) in cash | 7,167 | (7,500 | ) | |||||
Cash, beginning of period | 2,618 | 10,118 | ||||||
Cash, end of period | $ | 9,785 | $ | 2,618 | ||||
Non-cash investing activities: | ||||||||
Equipment purchased in accounts payable | 197 | - | ||||||
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
What was Champions Oncology's (CSBR) revenue for fiscal year 2025?
How much profit did CSBR make in fiscal year 2025?
What was Champions Oncology's Q4 2025 performance?
How much revenue did CSBR's data licensing business generate?
What is Champions Oncology's current cash position?
